Arovella Therapeutics Limited
Arovella Therapeutics Limited
Your view on ALA.AX
Overview
What the company does, where it operates, and who runs it.
About Arovella Therapeutics Limited
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Nicole van der Weerden
- Headquarters
- Corporate One, Preston, VIC, AU
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Nicole van der Weerden
- Headquarters
- Corporate One, Preston, VIC, AU
Arovella Therapeutics Limited, an Australian biotechnology firm, is dedicated to developing therapeutic solutions for oncology and central nervous system afflictions, operating both domestically and internationally.
Its pipeline features several key assets, including ZolpiMist, an oral spray formulation of zolpidem tartrate for the treatment of short-term insomnia, commercially known by brands such as Ambien or Stilnox. The company is also advancing an invariant natural killer T (iNKT) cell therapy platform specifically designed to target blood cancers.
Furthermore, Arovella employs OroMist, an oro-mucosal technology enabling the delivery of various drug classes through absorption in the oral cavity via the cheeks, gums, tongue, or mouth floor, and is developing Anagrelide for cancer treatment.
Beyond these, the company is engaged in creating oral sprays to address conditions like migraine headaches, motion sickness, and drug-resistant epilepsy. Arovella maintains a research collaboration agreement with Imperial College London.
Established in 1999 and based in Osborne Park, Australia, the company was formerly known as Suda Pharmaceuticals Ltd before rebranding to Arovella Therapeutics Limited in October 2021.
Stock Data
Price chart, volume, and trading data.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
About this section
Valuation, profitability, liquidity and leverage ratios for Arovella Therapeutics Limited. Starting points for Arovella Therapeutics Limited: EPS -AUD 0.0057, beta 0.13 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
About this section
Dividend history, yield and payout sustainability for Arovella Therapeutics Limited. Arovella Therapeutics Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
About this section
Reported vs. expected earnings history for Arovella Therapeutics Limited. Trailing twelve-month EPS for Arovella Therapeutics Limited stands at -AUD 0.0057. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
About this section
Income statement, balance sheet and cash flow history for Arovella Therapeutics Limited. Arovella Therapeutics Limited has reported as a listed company since 2002. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
| Ticker | Type | Company | Sector | Exchange | Mkt cap |
|---|---|---|---|---|---|
| PBLSParabilis Medicines, Inc. | Healthcare | NASDAQ | $3.3B | ||
| PBMPsyence Biomedical Ltd. | Healthcare | NASDAQ | $56,486 | ||
| PBMWWPsyence Biomedical Ltd. Warrant | Healthcare | NASDAQ | $973 | ||
| PBYIPuma Biotechnology, Inc. | Healthcare | NASDAQ | $364.5M | ||
| PCSAProcessa Pharmaceuticals, Inc. | Healthcare | NASDAQ | $4.4M | ||
| PCVXVaxcyte, Inc. | Healthcare | NASDAQ | $8.8B | ||
| PDSBPDS Biotechnology Corporation | Healthcare | NASDAQ | $43.4M | ||
| PEPGPepGen Inc. | Healthcare | NASDAQ | $261.8M | ||
| PFNDPathfinder Cell Therapy, Inc. | Healthcare | OTC | $66,716 | ||
| PGENPrecigen, Inc. | Healthcare | NASDAQ | $1.5B | ||
| PHARPharming Group N.V. | Healthcare | NASDAQ | $814.5M | ||
| PHATPhathom Pharmaceuticals, Inc. | Healthcare | NASDAQ | $378.8M | ||
News
Latest headlines and market coverage.
About this section
Latest headlines and company announcements for Arovella Therapeutics Limited. Coverage tracks Arovella Therapeutics Limited within Biotechnology (Healthcare). Press releases and market coverage, newest first.

Comments
Comments and replies from FRC members about this company.
No comments yet
Be the first to ask a question or say what you make of Arovella Therapeutics Limited.